

AVTECH - Stable with optionality

Redeye states the report was in line with expectaions. AVTECH has an attractive pipeline of potential airlines scheduled for trial in 2023-2024. Our estimates reflect c50% of this potential to convert to sales over the same period. We have increased our base case by c20%.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

AVTECH - Stable with optionality